Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Published Erratum
. 2022 Aug 30:378:o2094.
doi: 10.1136/bmj.o2094.

Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis

No authors listed
Published Erratum

Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis

No authors listed. BMJ. .
No abstract available

PubMed Disclaimer

Figures

Fig 1
Fig 1
Forest plot of estimated effects (95% confidence intervals) of a 0.1 decrease in standardized uptake value ratio on mini-mental state examination score for each trial and drug (top panel) and pooled across all drugs and by drug type (bottom panel). Trials of BAN2401 (Lecanemab) and Aducanumab are unpublished and were excluded from the “all published antibody” category. Centre and width of diamonds represent pooled estimates and 95% confidence intervals, respectively
Fig 2
Fig 2
Forest plot of estimated effects (95% confidence intervals) of a 0.1 decrease in standardized uptake value ratio on mini-mental state examination score stratified by radiotracer. The “all trials scaled” estimate scales the standardized uptake value ratios so that each tracer is approximately on the same scale (1/100th of a centiloid transformation)
Fig 3
Fig 3
Forest plot of estimated effects (95% confidence intervals) of a 0.1 decrease in standardized uptake value ratio on the Alzheimer’s disease assessment scale-cognitive subscale (ADAS-Cog) for each trial and drug. Change is signed such that positive change represents increased cognitive performance relative to no change in standardized uptake value ratio. Numbered key is given for multiple trials of the same drug (see supplementary table S2 of the full paper for clinical trial numbers). The version of the ADAS-Cog is given in parentheses
Fig 4
Fig 4
Forest plot of estimated effects (95% confidence intervals) of a 0.1 decrease in standardized uptake value ratios on the clinical dementia rating scale-sum of boxes (CDR-SB) for each trial and drug. Change is signed such that positive change represents increased cognitive performance relative to no change in standardized uptake value ratio. Numbered key is given for multiple trials of the same drug (supplementary table S2 of the full paper for clinical trial numbers). Trial LY450139-2 was removed because the corresponding estimate was uninformative (ie, all slopes were plausible)
See this image and copyright information in PMC

Erratum for

References

    1. Pang M, Zhu L, Gabelle A, et al. . Effect of reduction in brain amyloid levels on change in cognitive and functional decline in randomized clinical trials: an updated instrumental variable meta-analysis. medRxiv 2022. 10.1101/2022.04.01.22273253. - DOI - PubMed
    1. Egan MF, Kost J, Voss T, et al. . Randomized trial of Verubecestat for prodromal Alzheimer’s disease. N Engl J Med 2019;380:1408-20. 10.1056/NEJMoa1812840 - DOI - PMC - PubMed

Publication types

LinkOut - more resources